Answers are grounded in this paper and cite their sources.
Treatment with blinatumomab resulted in significantly longer overall survival than chemotherapy among adult patients with relapsed or refractory B-cell precursor ALL. (Funded by Amgen; TOWER ClinicalTrials.gov number, NCT02013167 .).
No takes yet. Share an insight, caveat, or question.
Kantarjian et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: